Eli Lilly
Pharmaceuticals · United States
Eli Lilly discovers, makes and sells prescription medicines, led by the weight-loss and diabetes drugs Mounjaro and Zepbound, plus cancer, immunology and neuroscience treatments, mostly through wholesalers.
What makes it different
One molecule, sold as two drugs, earns over half its revenue.
56%Of revenue from Mounjaro and ZepboundFY2025
Tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity.
How big it is
How big is Eli Lilly?
$65.2BTotal revenueFY2025
50,000EmployeesFY2025
90CountriesFY2025
How it makes money FY2025
Two weight and diabetes drugs lead.
- Mounjaro35%$23.0B
- Zepbound21%$13.5B
- Verzenio9%$5.7B
- Other products35%$22.9B
How the business works
Invent. Build capacity. Sell direct.
- 1Incretin and cancer medicines
- 2Manufacturing ahead of demand
- 3Via wholesalers and LillyDirect
Capacity is the limit: capital spending reached $7.8 billion in 2025 and is expected to rise meaningfully.
Who owns it
- Lilly Endowment Inc.9.8%
- The Vanguard Group8.6%
- BlackRock, Inc.6.8%
CEO: David A. Ricks
Who it competes with
Key moments
- 1876Colonel Eli Lilly founds the company in Indianapolis
- 1923Introduces Iletin, the first commercial insulin
- 1982Introduces Humulin, the first rDNA human-health product
- 2019Acquires Loxo Oncology, its largest acquisition to date
- 2022Introduces Mounjaro
Sources
Every number on this page comes from Eli Lilly's own reports.
Full profile
The rest of the story is in the app.
What Eli Lilly tracks21 metrics
Phase 3 potential indications in development
Employees
Items in regulatory review
Results, quarter by quarterwith a chart
Revenue
Profit
Margin
Where the money comes from5 regions
United States
Europe
Japan
The full timeline15 moments
2023
2024
2025
Eli Lilly vs Novo Nordiskside by side
Revenue
Profit
People
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
